Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 4:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ortho Cyclen® Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects

NCT02080468
View directory record Official record
Conditions
Healthy
Interventions
lomitapide, EE/norgestimate
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2019 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females

NCT02792517
View directory record Official record
Conditions
Headache, Migraine
Interventions
Erenumab, Ethynil Estradiol/Norgestimate Oral Contraceptive
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
4
States / cities
Anaheim, California • Cypress, California • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Sep 19, 2026, 4:48 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity

NCT00439972
View directory record Official record
Conditions
Contraception
Interventions
Ortho-Cyclen (R), Ortho Evra (R), extended use of Ortho Evra (R)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 13, 2011 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects

NCT01860703
View directory record Official record
Conditions
Prolonged QTc Interval
Interventions
Deferiprone, deferiprone matching placebo tablets, moxifloxacin, placebo
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 11, 2014 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers

NCT02236026
View directory record Official record
Conditions
Healthy
Interventions
Supratherapuetic dose of Nestorone, Placebo, Moxifloxacin
Drug
Lead sponsor
Population Council
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Sep 19, 2026, 4:48 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban

NCT02213029
View directory record Official record
Conditions
Embryo Transfer
Interventions
Epelsiban, Placebo, Oxytocin, Ortho-Cylcen (21)® tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2017 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects

NCT00983957
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
BMS-790052, Ortho Tri-Cyclen®
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Tempe, Arizona • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects

NCT02164812
View directory record Official record
Conditions
HIV/AIDS
Interventions
Moxifloxacin, Placebo, Efavirenz
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2015 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis

NCT00464438
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
gatifloxacin, moxifloxacin 0.5% eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
Up to 31 Days
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 1 Interventional

Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects

NCT00310596
View directory record Official record
Conditions
Healthy
Interventions
Gadopentetate dimeglumine (Magnevist, BAY86-4882), Moxifloxacin (BAY12-8039), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

NCT02056392
View directory record Official record
Conditions
Solid Tumours
Interventions
Selumetinib, Moxifloxacin, selumetinib placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2015 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Staccato Loxapine Thorough QT/QTc Study

NCT00874237
View directory record Official record
Conditions
Thorough QT/QTc Study
Interventions
Inhaled loxapine, Inhaled placebo, Oral moxifloxacin, Oral placebo
Drug
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women

NCT01475513
View directory record Official record
Conditions
Insulin Sensitivity, Cardiovascular Risk, Perimenopausal Disorder
Interventions
Ortho Cyclen®
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

NCT01999114
View directory record Official record
Conditions
ECG Effects
Interventions
Buprenorphine transdermal patch, Naltrexone tablet, Placebos (for TDS and for naltrexone and for moxifloxacin), Moxifloxacin tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 55 Years
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol

NCT01243580
View directory record Official record
Conditions
Healthy
Interventions
Ortho-Cyclen, AG200-15
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms

NCT00874887
View directory record Official record
Conditions
Anti-biotic Resistance
Interventions
moxifloxacin 0.5% HCI ophthalmic solution, gatifloxacin ophthalmic solution 0.3%
Drug
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2011 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects

NCT02637193
View directory record Official record
Conditions
Healthy Subjects
Interventions
Venlafaxine, Moxifloxacin, Drug - placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers

NCT01290900
View directory record Official record
Conditions
Healthy Male Volunteers
Interventions
NXL104, Ceftaroline, Placebo Infusion, Ceftazidime, Moxifloxacin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.

NCT00721344
View directory record Official record
Conditions
Healthy Subjects
Interventions
Technosphere Inhalation Powder (FDKP), Moxifloxacin, Placebo
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers

NCT03258515
View directory record Official record
Conditions
Solid Tumors
Interventions
AZD6094 200 mg, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Results available

Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora

NCT00312338
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
VIGAMOX
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
1 Year to 13 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Oral Contraceptive Pill (OCP)

NCT01063023
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Ortho Tri-Cyclen®, BMS-650032
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Staccato Prochlorperazine Thorough QT/QTc

NCT00543062
View directory record Official record
Conditions
Cardiotoxicity
Interventions
Inhaled placebo, Oral placebo, Inhaled prochlorperazine 5 mg, Inhaled prochlorperazine 10 mg, Oral moxifloxacin
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 10, 2019 · Synced Sep 19, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

NCT01191723
View directory record Official record
Conditions
Healthy
Interventions
MAP0004, Inhaler Placebo, Moxifloxacin, Placebo Capsule
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Sep 19, 2026, 4:48 PM EDT